Employment |
No Relationships to Disclose |
|
|
Leadership |
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests |
Company: Cambium Oncology |
Recipient: You |
Company: Taobob LLC |
Recipient: You |
Company: GenCart |
Recipient: You |
Company: Coherus Biosciences |
Recipient: You |
|
Honoraria |
No Relationships to Disclose |
|
|
Consulting or Advisory Role |
Company: Novartis |
Recipient: You |
Company: Celgene |
Recipient: You |
Company: Abbvie |
Recipient: You |
Company: Eisai |
Recipient: You |
Company: G1 Therapeutics |
Recipient: You |
Company: Takeda |
Recipient: You |
Company: Bristol-Myers Squibb |
Recipient: You |
Company: MedImmune |
Recipient: You |
Company: BerGenBio |
Recipient: You |
Company: Lilly |
Recipient: You |
Company: Amgen |
Recipient: You |
Company: AstraZeneca |
Recipient: You |
Company: PharmaMar |
Recipient: You |
Company: Boehringer Ingelheim |
Recipient: You |
Company: EMD Serono |
Recipient: You |
Company: Xcovery |
Recipient: You |
Company: Bayer |
Recipient: You |
Company: Merck |
Recipient: You |
Company: Jazz Pharmaceuticals |
Recipient: You |
Company: Zentalis |
Recipient: You |
Company: Wells Fargo |
Recipient: You |
Company: Ipsen |
Recipient: You |
Company: Eisai |
Recipient: You |
Company: Roche/Genentech |
Recipient: You |
Company: Janssen |
Recipient: You |
Company: Exelixis |
Recipient: You |
Company: BeiGene |
Recipient: You |
Company: Triptych Health Partners |
Recipient: You |
Company: Daichi |
Recipient: You |
Company: Xcovery |
Recipient: You |
Company: Coherus Biosciences |
Recipient: You |
|
Speakers' Bureau |
Company: Abbvie |
Recipient: You |
|
Research Funding |
Company: Corvus Pharmaceuticals |
Recipient: You |
Company: Novartis |
Recipient: Your Institution |
Company: Astellas Pharma |
Recipient: Your Institution |
Company: Bayer |
Recipient: Your Institution |
Company: Regeneron |
Recipient: Your Institution |
Company: AstraZeneca/MedImmune |
Recipient: Your Institution |
Company: Abbvie |
Recipient: Your Institution |
Company: G1 Therapeutics |
Recipient: Your Institution |
Company: Bristol-Myers Squibb |
Recipient: Your Institution |
Company: United Therapeutics |
Recipient: Your Institution |
Company: Amgen |
Recipient: Your Institution |
Company: Loxo/Lilly |
Recipient: Your Institution |
Company: Fujifilm |
Recipient: Your Institution |
Company: Pfizer |
Recipient: Your Institution |
Company: Aeglea Biotherapeutics |
Recipient: Your Institution |
Company: Incyte |
Recipient: Your Institution |
Company: Merck |
Recipient: Your Institution |
Company: Oncorus |
Recipient: Your Institution |
Company: Ipsen |
Recipient: Your Institution |
Company: GlaxoSmithKline |
Recipient: Your Institution |
Company: Calithera Biosciences |
Recipient: Your Institution |
Company: Eisai |
Recipient: Your Institution |
Company: WindMIL |
Recipient: Your Institution |
Company: Turning Point Therapeutics |
Recipient: Your Institution |
Company: Roche/Genentech |
Recipient: Your Institution |
Company: Mersana |
Recipient: Your Institution |
Company: Meryx |
Recipient: Your Institution |
Company: Boehringer Ingelheim |
Recipient: Your Institution |
Company: Boehringer Ingelheim |
Recipient: Your Institution |
|
Patents, Royalties, Other Intellectual Property |
Please describe: OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS
THROUGH SUPPRESSION OF STAT3 |
Recipient: Your Institution |
Please describe: SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS
RELATED THERETO |
Recipient: Your Institution |
Please describe: DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor)
|
Recipient: Your Institution |
Please describe: Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) |
Recipient: Your Institution |
|
Expert Testimony |
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses |
No Relationships to Disclose |
|
|
Other Relationship |
Company: Roche/Genentech |
Recipient: You |
Company: EMD Serono |
Recipient: You |
Company: Novartis |
Recipient: You |
|
(OPTIONAL) Uncompensated Relationships |
Company: Reflexion Medical |
Recipient: You |
|
(OPTIONAL) Open Payments Link |
|
Open Payments URL: https://openpaymentsdata.cms.gov/physician/253457 |
|